Charles Lieber is one of the best-known figures in nanoscience, but his career took a dramatic turn after a U.S. federal conviction. Lieber, a former distinguished chemistry professor at Harvard University, was convicted in 2021 of making false statements to federal authorities and tax-related crimes related to payments from China. Today, he is back in his lab in Shenzhen, leading state-supported brain-computer interface research at i-BRAIN, a subsidiary of the Shenzhen Institute of Medical Research and Translation. The field is medically promising but also strategically sensitive, which is why his move to China attracted attention.
Charles Lieber’s journey from Harvard fame to federal conviction
Lieber built a long and influential career at Harvard University, where he joined the faculty in 1991 and subsequently served as chair of the Department of Chemistry and Chemical Biology from 2015 to 2020. He holds the prestigious Joshua and Beth Friedman University Professorship, one of Harvard University’s highest academic honors. For more than three decades, he became a leading figure in nanoscience, publishing hundreds of peer-reviewed papers and holding dozens of patents. His research focuses on nanomaterials and nanoelectronics, particularly devices capable of interfacing with biological systems, including early work related to neural interfaces and brain-computer technology. In December 2021, a federal jury convicted him of making false statements to federal authorities, filing false tax returns, and failing to disclose foreign bank accounts. In April 2023, he was sentenced to six months in prison, home confinement, a $50,000 fine, and repayment to the Internal Revenue Service. The case involves undisclosed participation in China’s Thousand Talents Program and payments from Chinese universities.
Charles Lieber currently leads research in China
Lieber’s move to Shenzhen marked an astonishing new chapter in a high-stakes scientific career. In April 2025, he came to Shenzhen to take charge of i-BRAIN, the Institute of Brain, Advanced Interfaces and Neurotechnology under the Shenzhen Academy of Medical Research and Translation (SMART). There he served as founding director and chair professor. His lab reportedly houses advanced nanofabrication tools and primate research facilities, providing him with resources that Harvard University cannot. For a scientist long associated with nanoelectronics, this environment is ideal for the next phase of his work.The field he now helps lead is brain-computer interfaces (BCI), which aim to convert brain activity into signals that computers can read and use. The technology already has medical promise. Researchers are exploring this in patients with ALS, paralysis and aphasia, and recent developments suggest neural signals could be converted into speech or used in a limited way to control devices. The field is moving steadily from laboratory experiments to clinical applications.China has prioritized brain-computer interfaces. In 2026, commercialized BCI medical devices were approved, aiming to help quadriplegic patients restore their hand grasping ability. This technology has been identified as a future industry in national planning. This policy support helps explain why Lieber’s presence is important. He brings extensive experience in nanofabrication, neural interfaces and advanced materials, expertise that can accelerate the development of research areas of humanitarian and strategic value.That’s why his new role remains controversial. Lieber was more than just a scientist starting over in a new country. He is a researcher convicted in the United States of making false statements related to China-related payments and relationships, and now works within a state-backed China research system that is investing heavily in emerging technologies. His story lies at the intersection of science, geopolitics and technological competition, making him one of the most closely watched figures in the global race to connect brains to machines.
